Page 2 - Pharmaceutical

Sigachi zooms 37% in 2 days on huge volumes; 130 mn shares change hands

Till 11:32 AM; as many as a combined 130 million equity shares representing 34 per cent of total equity of Sigachi changed hands on the NSE (112 million shares) and BSE (18 million shares).

GST on lifesaving drugs reduced to nil: Check full list of tax on medicines

GST Council meet outcome: GST on various medical apparatus and devices used for medical, surgical, dental or veterinary usage has been reduced to 5% from 12%

How Ozempic maker Novo Nordisk lost sheen after creating wonder drug

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed its fortunes

Weighty issues: India's rush to make weight-loss drugs demands user caution

The global market for weight-loss drugs is estimated at $100 billion by the end of the decade

Laurus rallies 6%, hits new high on strong Q1; brokerages see more upside

Laurus stock price outlook: Given the higher-margin profile of CDMO and operating leverage as new manufacturing assets ramp, brokerage firms expect sustained margin expansion.

Patel Chem Specialities SME IPO: Issue price band fixed at ₹82-84/share

Patel Chem Specialities, a manufacturer of starch-based pharmaceutical excipients, on Thursday fixed the price at Rs 82-84 per share for its Rs 58.80 crore initial public offering (IPO). The IPO will open on July 25 and conclude on July 29. The shares of the company will be listed on BSE's SME platform, Patel Chem Specialities said in a statement. The public issue is entirely a fresh issue of up to 70 lakh equity shares. Proceeds from the issue will be utilised to set up a plant at Indrad, Mahesana, for manufacturing Croscarmellose Sodium (CCS), Sodium Starch Glycolate (SSG) Corn Starch Base & Potato Starch Base and Calcium Carboxymethylcellulose (CMC) and general corporate purposes. Incorporated in 2008, Patel Chem Specialities is engaged in the manufacturing and exporting of pharmaceutical excipients and specialty chemicals. As of FY25, the company has an installed production capacity of 7,200 MT per year, with a capacity utilisation rate of 89 per cent. "The IPO proceeds will

Trump likely to announce pharma tariffs as high as 200% this month

Donald Trump's plan to impose pharma tariffs could hit Indian drugmakers like Biocon, Lupin, and Sun Pharma, with new levies starting August 1

Divis Labs bucks weak pharma shares trend; hits new high on strong Q1 hopes

In the past six months, the Divis Labs stock has outperformed the market by surging 18 per cent, as against 1.4 per cent fall in the BSE Healthcare index and 7 per cent rise in the BSE Sensex.

Biological E to make HPV9 vaccine under licensing pact with Recbio

BE to produce and commercialise Recbio's nine-valent HPV vaccine in India and global markets, including participation in UNICEF and PAHO tenders

Indian pharma eyes US gains as $63.7 bn patent cliff nears: Analysts

Shift is expected to drive a sharp increase in generic drug launches, positioning Indian drugmakers for strong growth

Pharma majors turn to acquisitions as cash stockpile hits ₹49,000 crore

India's top drugmakers are reportedly sitting on their highest cash reserves in at least five years, up over 120% from FY20

Zydus Wellness Q4 result: Profit rises 14.4% to Rs 171.9 cr on strong sales

Zydus Wellness Ltd on Monday reported a 14.4 per cent rise in consolidated net profit at Rs 171.9 crore in the fourth quarter ended March 31, 2025, driven by strong performance of its food and nutrition as well as personal care segments. The company had posted a consolidated net profit of Rs 150.3 crore in the same quarter of the previous fiscal. The board of the company has approved the sub-division of its stock with one equity share of face value of Rs 10 to be split into five equity shares of face value Rs 2 each, subject to shareholders' approval. Consolidated total revenue from operations in the fourth quarter stood at Rs 910.6 crore, as compared to Rs 778 crore in the year-ago period, Zydus Wellness Ltd said in a regulatory filing. Total expenses in the quarter under review were higher at Rs 740.5 crore, as compared to Rs 632.2 crore in the corresponding period a year ago. With the continued thrust on marketing initiatives, several key brands including Nutralite, Glucon-D, .

Lupin Q4 results: Net profit zooms by 112% to ₹782 cr, revenue up 14%

The company's revenue from operations rose 14.2 per cent Y-o-Y to ₹5,671 crore, from ₹4,961 crore in Q4FY24

USFDA issues 6 observations to Zydus' Gujarat API unit after inspection

Zydus Lifesciences on Saturday said the US health regulator has issued six observations after inspecting its Gujarat-based API manufacturing unit. "We wish to inform that the US Food and Drug Administration (USFDA) conducted a surveillance inspection at the group's API (active pharmaceutical ingredient) unit located at Dabhasa in Gujarat," the drug firm said in a regulatory filing. The inspection was conducted from April 21-25, 2025. "The inspection concluded with 6 observations and none of them were related to data integrity," Zydus Lifesciences said. The company is confident of addressing the observations expeditiously, it added.

Eli Lilly's first weight-loss pill shows success in initial Phase 3 trials

Lilly CEO says if approved, drug could be manufactured and launched at scale globally

US tops India's pharma exports with $9.8 bn share in April-Feb FY25

Exports to the US grew 14% in April-February FY25

Emcure arm Tillomed acquires Manx Pharma portfolio for Rs 218.67 cr

The deal includes the purchase of product dossiers, marketing authorisations, intellectual property, and inventory

Peter Bains steps down as Group CEO of Biocon, to serve Syngene's MD & CEO

Furthermore, Biocon has scheduled a board meeting on April 4 to discuss and approve fundraising for its commercial business

NCLT approves amalgamation of Suven Pharma, Cohance Lifesciences

As per the scheme's terms, the merger will take effect from the first business day of the month following the fulfilment of all conditions

Diarrhoea and viral infections spur sales of probiotics, shows data

Antidiarrheals and anti-flatulents have also grown in strong double digits - 36 per cent and 29 per cent, respectively